10x Genomics To Incorporate Lunit's AI-Powered Pathology Platform Into Its Oncology Biomarker Discovery Workflow
Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that 10x Genomics, Inc. (Nasdaq: TXG) will incorporate Lunit's AI-powered pathology platform, Lunit SCOPE
10x Genomics is adding Lunit's AI tool that helps doctors spot cancer patterns in body samples. This shows 10x is building stronger tools for cancer research, which could make their work more useful.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.